Attached files
file | filename |
---|---|
EX-99.01 - PRESS RELEASE - Inspyr Therapeutics, Inc. | v372105_ex99-01.htm |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 18, 2014
GENSPERA, INC.
(Exact name of registrant as specified in Charter)
Delaware | 0001421204 | 20-0438951 | ||
(State or other jurisdiction of incorporation or organization) |
(Commission File No.) | (IRS Employee Identification No.) |
2511 N Loop 1604 W, Suite 204
San Antonio, TX 78258
(Address of Principal Executive Offices)
210-479-8112
(Issuer Telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 | Other Events. |
On March 18, 2014, GenSpera, Inc. (the “Company”) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme. A copy of the press release is attached to this report as Exhibit 99.01.
Item 9.01. | Financial Statements and Exhibits. |
Exhibit No. |
Description |
|
99.01 | Press Release dated March 18, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 18, 2014
GenSpera, Inc. | ||
By: | /s/ Craig Dionne | |
Craig Dionne Chief Executive Officer |
INDEX OF EXHIBITS
Exhibit No. |
Description |
|
99.01 | Press Release dated March 18, 2014 |